Pfizer Inc. (PFE)

LobbyFacts currently only presents data from the EU lobby transparency register up to 19 September 2021. This is due to recent changes made by the EU register; we are working to present these on LobbyFacts as soon as possible.

Tweet this page
<
>
How to read and use this data card.
LOADING...
1717450
e3e0d84bb7a04c7abeb52143d8273b0c

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

1,250,000€ - 1,499,999€

Financial year: 01/01/2020 - 01/12/2020

Lobbyists declared: 2 FTE (6)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.

1
1

Lobbyists with EP accreditation: 3

1
1
1

Meetings with European Commission: 13

Lobbying costs over the years:

1
5
10
100
1000

Pfizer Inc. (PFE)

Registration on EU Transparency Register

4263301811-33 (First registered: 18 Dec 2008)

Goals / Remit

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. In 2020 Pfizer's full year revenue was $42 billion, with approx. 9.4bn invested in research and development. To learn more, please visit us at www.pfizer.com.

Issues

EU Incentives review, pharmaceutical strategy, Pediatric & Orphan Review, Joint actions related to AMR, Vaccines and HTA, HTA Regulation proposal, Pharmaceuticals in the Environment, IMI and research programs, trade negotiations, tax such as proposal on public country-by-country reporting (CBCR), Covid 19 vaccines & therapeutics procurement, HERA & biopreparedness.

Address

Head office:
East 42nd Street, 235
New York NY 10017
United States

Tel: 1 2127332323

Belgium office:
Boulevard de la Plaine 17
Brussels 1050,
Belgium

Tel: 32 25546211